Although osimertinib was approved for advanced NSCLC with acquired T790M mutation, chemotherapy has remained the clinically preferred subsequent treatment for T790M-negative patients with PD after 1st/2nd-generation EGFR-TKI therapies; furthermore, drugs targeting mutations other than T790M are still under investigation in clinical trials (29). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.